The University Medical Center Utrecht in the Netherlands will begin a study comparing Kuros Biosciences' MagnetOs with autologous bone in posterolateral spinal fusion.
Here are three things to know:
1. The five-center randomized clinical trial will enroll 100 adult patients who qualify for posterolateral spinal fusion in the thoracolumbar and lumbosacral region. The study's primary endpoint is posterior spinal fusion rate after one year based on CT scans.
2. MagnetOs is a bone graft substitute designed to fill bony voids and promote bone formation at the implanted site.
3. MagnetOs is comprised of biphasic calcium phosphate with a submicron surface topography intended to direct bone formation after implantation.
More articles on biologics:
Cerapedics earns 2018 MedTech Breakthrough Award for i-FACTOR bone graft— 5 highlights
Edison Healthcare offers employees biologic-based alternatives to orthopedic surgery: 3 insights
NuVasive launches AttraX Scaffold biologic: 4 things to know